An Open-Label Study to Evaluate Efficacy and Safety of Long-term Treatment With ACH-0144471 in Patients Who Completed Clinical Study ACH471-100
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Danicopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Achillion Pharmaceuticals
- 19 Aug 2019 Planned End Date changed from 1 Dec 2019 to 30 Dec 2020.
- 19 Aug 2019 Planned primary completion date changed from 1 Dec 2019 to 30 Dec 2020.
- 19 Aug 2019 Status changed from recruiting to active, no longer recruiting.